Skip to content

Study · Animal study (in vivo) · mouse · 2017

3 results

The AMPK Activator Aicar Ameliorates Age-Dependent Myocardial Injury in Murine Hemorrhagic Shock.

Matsiukevich D, Piraino G, Klingbeil LR, Hake PW, Wolfe V, O'Connor M, Zingarelli B

Shock (Augusta, Ga.)1 Jan 2017Cited by 17 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In young and mature mice with hemorrhagic shock, AICAR ameliorated myocardial damage in both age groups.

    In plain wordsIn mice with hemorrhagic shock, AICAR reduced heart damage in both age groups compared with vehicle.

    Outcome
    DecreaseMyocardial damage
    Study

    mousen: not reported in source

    Hemorrhagic shock
    Comparator
    Vehicle
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with AICAR ameliorated myocardial damage in both age groups.
    2 context sentences
    Summary · context
    Anesthetized C57/BL6 young (3-5 months old) and mature (9-12 months old) male mice were subjected to hemorrhagic shock by blood withdrawing followed by resuscitation with shed blood and Lactated Ringer's solution.
    Summary · context
    Mice were sacrificed at 3 h after resuscitation, and plasma and hearts were harvested for biochemical assays.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In hemorrhagic shock, AICAR reduced myocardial injury less effectively in mature mice than young mice.

    In plain wordsIn mice with hemorrhagic shock, AICAR reduced heart injury less effectively in mature mice than young mice.

    Outcome
    DecreaseCardioprotective efficacy in mature versus young mice
    Study

    mousen: not reported in source

    Hemorrhagic shock
    Comparator
    Young mice receiving AICAR
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, AICAR therapeutic effects were less effective in mature mice than young mice and involved distinct mechanisms of action.
    2 context sentences
    Summary · context
    Anesthetized C57/BL6 young (3-5 months old) and mature (9-12 months old) male mice were subjected to hemorrhagic shock by blood withdrawing followed by resuscitation with shed blood and Lactated Ringer's solution.
    Summary · context
    Mice were sacrificed at 3 h after resuscitation, and plasma and hearts were harvested for biochemical assays.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice with hemorrhagic shock, AICAR therapeutic effects involved distinct mechanisms in mature and young animals.

    In plain wordsIn mice with hemorrhagic shock, AICAR acted through different mechanisms in mature and young animals.

    Outcome
    Direction not reportedAge-dependent mechanism of action
    Study

    mousen: not reported in source

    Hemorrhagic shock
    Comparator
    Young mice receiving AICAR
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, AICAR therapeutic effects were less effective in mature mice than young mice and involved distinct mechanisms of action.
    2 context sentences
    Summary · context
    Anesthetized C57/BL6 young (3-5 months old) and mature (9-12 months old) male mice were subjected to hemorrhagic shock by blood withdrawing followed by resuscitation with shed blood and Lactated Ringer's solution.
    Summary · context
    Mice were sacrificed at 3 h after resuscitation, and plasma and hearts were harvested for biochemical assays.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.